Read our monthly recap of some of the biggest FDA-related stories that have hit cardiology, including updates related to Cytokinetics, Dexcom and Abiomed. 

Brian Lindman, MD, discusses the tracking of TAVR devices for signs of deterioration and how to assess long-term durability.

Researchers explored nearly 20 years of data from more than 18,000 patients, sharing their findings in the Journal of the American Heart Association.

Pediatric cardiologist Takeshi Tsuda, MD, discussed the evaluation of cardiotoxicity in young cancer patients at the American Heart Association (AHA) 2022 meeting.

The recall includes more than 2,000 devices distributed to customers in 2022. There have been 241 complaints, and 135 reported pump stops, related to this issue. 

ACC President Edward T.A. Fry, MD, explains the need to better develop the cardiology workforce as the subspecialty faces a looming shortage of cardiologists. 

Even after adjusting for factors such as income, comorbidities and stroke severity indicators, a prolonged length of stay was more common for Black patients.

The company's most well-known product within the industry is the CorPath GRX System, a second-generation robotics solution used by interventional cardiologists during PCI and other interventional procedures.

Gabler, a Texas native, has two decades of experience in the cardiology space, spending the last 11 years with Edwards Lifesciences. He has also previously worked for both Medtronic and Boston Scientific.

Healthcare stakeholders throughout U.S. medicine, including radiology leaders, aren’t waiting for the ink to dry before speaking their minds.

A population-level study featuring multi-organ MRI has confirmed that problems in any of three major organs—the heart, brain or liver—tend to co-occur with unfavorable findings in either or both of the other two.